Welcome to our dedicated page for Opthea SEC filings (Ticker: OPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Opthea Limited (OPT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Opthea files reports on Form 20-F and Form 6-K, along with other forms such as Form 25, in connection with its American Depositary Shares representing ordinary shares listed on The Nasdaq Global Select Market.
Through its Form 6-K current reports, Opthea furnishes documents such as preliminary final reports, half-year reports, quarterly updates, and press releases. These filings often include information on clinical development of sozinibercept in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), financial results, cash position, capital raising activities, and significant corporate events. Some 6-Ks incorporate press releases announcing clinical milestones, manufacturing progress, management changes, and strategic decisions, including the settlement of a Development Funding Agreement and related implications for the company’s solvency and operations.
Form 20-F annual reports, referenced in Opthea’s forward-looking statement disclosures, provide more comprehensive information on risk factors, business description, and financial statements. In addition, a Form 25 filed on November 10, 2025, notifies the voluntary removal of Opthea’s American Depositary Shares from listing and registration on The Nasdaq Global Select Market under Section 12(b) of the Securities Exchange Act of 1934, indicating that the issuer has complied with the applicable rules for voluntary withdrawal.
On Stock Titan, these SEC filings are presented alongside AI-powered summaries that aim to highlight key points from lengthy documents, such as clinical program updates, financing terms, and listing status changes. Investors can use this page to review Opthea’s historical and current U.S. regulatory filings, understand how its retinal disease programs and capital structure are described to regulators, and track formal announcements related to its securities.
Opthea Limited filed a Form 25 to remove its American Depositary Shares from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The securities are ADSs, each representing eight ordinary shares, previously listed on The Nasdaq Global Select Market. The notification was signed by Chief Executive Officer Jeremy Levin on November 10, 2025.
Opthea Limited filed a Form 6-K noting it issued a press release announcing its intention to voluntarily delist its American Depositary Shares from the Nasdaq Global Select Market.
The press release, dated October 29, 2025, is furnished as Exhibit 99.1 and is incorporated by reference into Opthea’s Form S-8 (File No. 333-251052). This notice focuses on the planned delisting of Opthea’s ADSs from Nasdaq as described in the press release.
FAQ
What is the current stock price of Opthea (OPT)?
What is the market cap of Opthea (OPT)?
